Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Orthostatic plasma norepinephrine level as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome

Authors: Qingyou Zhang, Xia Chen, Jiawei Li, Junbao Du

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

Postural tachycardia syndrome (POTS) is a heterogeneous disorder that creates challenges for treatment. Beta-blocker was one of the most commonly used drugs, but it is inconsistently effective. The purpose of this study is to explore whether orthostatic plasma norepinephrine level could be an indicator of therapeutic effectiveness of metoprolol for POTS in children.

Methods

Twenty-seven children with POTS were enrolled in our study. They received metoprolol treatment, and their orthostatic plasma norepinephrine levels were measured by high-performance liquid chromatography method. Three months after rmetoprolol treatment, 25 patients were followed up. A receiver-operating characteristic (ROC) curve was used to explore the predictive value of orthostatic plasma norepinephrine level.

Results

The symptom severity and increment of heat rate from supine position to upright of patients positively correlated with their orthostatic plasma norepinephrine level (r = 0.599, P < 0.001; r = 0.633, P <0.001, respectively). Orthostatic plasma norepinephrine level in responders to metoprolol was significantly higher than that of nonresponders (P = 0.028). A ROC curve on the predictive value of orthostatic plasma norepinephrine level showed that the area under the curve was 0.785. Using a cutoff value for orthostatic plasma norepinephrine level of 3.59 pg/ml yielded both sensitivity (76.9%) and specificity (91.7%) in predicting the efficacy of metoprolol therapy for POTS.

Conclusion

Orthostatic plasma norepinephrine level of > 3.59 pg/ml was an indicator of the effectiveness of metoprolol therapy for POTS in children and adolescents.
Appendix
Available only for authorised users
Literature
1.
go back to reference Medow MS: Postural tachycardia syndrome from a pediatrics perspective. J Pediatr. 2011, 158: 4-6. 10.1016/j.jpeds.2010.08.038.CrossRefPubMed Medow MS: Postural tachycardia syndrome from a pediatrics perspective. J Pediatr. 2011, 158: 4-6. 10.1016/j.jpeds.2010.08.038.CrossRefPubMed
2.
go back to reference Jarjour IT: Postural tachycardia syndrome in children and adolescents. Semin Pediatr Neurol. 2013, 20: 18-26. 10.1016/j.spen.2013.01.001.CrossRefPubMed Jarjour IT: Postural tachycardia syndrome in children and adolescents. Semin Pediatr Neurol. 2013, 20: 18-26. 10.1016/j.spen.2013.01.001.CrossRefPubMed
3.
go back to reference Johnson JN, Mack KJ, Kuntz NL, Brands CK, Porter CJ, Fischer PR: Postural orthostatic tachycardia syndrome: a clinical review. Pediatr Neurol. 2010, 42: 77-85. 10.1016/j.pediatrneurol.2009.07.002.CrossRefPubMed Johnson JN, Mack KJ, Kuntz NL, Brands CK, Porter CJ, Fischer PR: Postural orthostatic tachycardia syndrome: a clinical review. Pediatr Neurol. 2010, 42: 77-85. 10.1016/j.pediatrneurol.2009.07.002.CrossRefPubMed
4.
go back to reference Benarroch EE: Postural tachycardia syndrome: a heterogeneous and multifactorial disorder. Mayo Clin Proc. 2012, 87: 1214-1225. 10.1016/j.mayocp.2012.08.013.PubMedCentralCrossRefPubMed Benarroch EE: Postural tachycardia syndrome: a heterogeneous and multifactorial disorder. Mayo Clin Proc. 2012, 87: 1214-1225. 10.1016/j.mayocp.2012.08.013.PubMedCentralCrossRefPubMed
5.
go back to reference Benrud-Larson LM, Dewar MS, Sandroni P, Rummans TA, Haythornthwaite JA, Low PA: Quality of life in patients with postural tachycardia syndrome. Mayo Clin Proc. 2002, 77: 531-537. 10.4065/77.6.531.CrossRefPubMed Benrud-Larson LM, Dewar MS, Sandroni P, Rummans TA, Haythornthwaite JA, Low PA: Quality of life in patients with postural tachycardia syndrome. Mayo Clin Proc. 2002, 77: 531-537. 10.4065/77.6.531.CrossRefPubMed
6.
go back to reference Wyller VB, Thaulow E, Amlie JP: Treatment of chronic fatigue and orthostatic intolerance with propranolol. J Pediatr. 2007, 150: 654-655. 10.1016/j.jpeds.2007.03.012.CrossRefPubMed Wyller VB, Thaulow E, Amlie JP: Treatment of chronic fatigue and orthostatic intolerance with propranolol. J Pediatr. 2007, 150: 654-655. 10.1016/j.jpeds.2007.03.012.CrossRefPubMed
7.
go back to reference Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF: Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res. 2000, 10: 293-299. 10.1007/BF02281112.CrossRefPubMed Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF: Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res. 2000, 10: 293-299. 10.1007/BF02281112.CrossRefPubMed
8.
go back to reference Raj SR, Black BK, Biaggioni I, Paranjape SY, Ramirez M, Dupont WD, Robertson D: Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. 2009, 120: 725-734. 10.1161/CIRCULATIONAHA.108.846501.PubMedCentralCrossRefPubMed Raj SR, Black BK, Biaggioni I, Paranjape SY, Ramirez M, Dupont WD, Robertson D: Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. 2009, 120: 725-734. 10.1161/CIRCULATIONAHA.108.846501.PubMedCentralCrossRefPubMed
9.
go back to reference Zhang Q, Du J, Wang Y: The efficacy of β-blocker plus oral saline in the treatment of children with postural orthostatic tachycardia syndrome. J Clin Pediatr (Chinese). 2006, 24: 357-362. Zhang Q, Du J, Wang Y: The efficacy of β-blocker plus oral saline in the treatment of children with postural orthostatic tachycardia syndrome. J Clin Pediatr (Chinese). 2006, 24: 357-362.
10.
go back to reference Arnold AC, Okamoto LE, Diedrich A, Paranjape SY, Raj SR, Biaggioni I, Gamboa A: Low-dose propranolol and exercise capacity in postural tachycardia syndrome: a randomized study. Neurology. 2013, 80: 1927-1933. 10.1212/WNL.0b013e318293e310.PubMedCentralCrossRefPubMed Arnold AC, Okamoto LE, Diedrich A, Paranjape SY, Raj SR, Biaggioni I, Gamboa A: Low-dose propranolol and exercise capacity in postural tachycardia syndrome: a randomized study. Neurology. 2013, 80: 1927-1933. 10.1212/WNL.0b013e318293e310.PubMedCentralCrossRefPubMed
11.
go back to reference Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD: Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 2011, 58: 167-175. 10.1161/HYPERTENSIONAHA.111.172262.PubMedCentralCrossRefPubMed Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD: Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 2011, 58: 167-175. 10.1161/HYPERTENSIONAHA.111.172262.PubMedCentralCrossRefPubMed
12.
go back to reference Lai CC, Fischer PR, Brands CK, Fisher JL, Porter CB, Driscoll SW, Graner KK: Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and β-blockers. Pacing Clin Electrophysiol. 2009, 32: 234-238. 10.1111/j.1540-8159.2008.02207.x.CrossRefPubMed Lai CC, Fischer PR, Brands CK, Fisher JL, Porter CB, Driscoll SW, Graner KK: Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and β-blockers. Pacing Clin Electrophysiol. 2009, 32: 234-238. 10.1111/j.1540-8159.2008.02207.x.CrossRefPubMed
13.
go back to reference Ladage D, Schwinger RH, Brixius K: Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. Cardiovasc Ther. 2013, 31: 76-83. 10.1111/j.1755-5922.2011.00306.x.CrossRefPubMed Ladage D, Schwinger RH, Brixius K: Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. Cardiovasc Ther. 2013, 31: 76-83. 10.1111/j.1755-5922.2011.00306.x.CrossRefPubMed
14.
go back to reference Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG: Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011, 21: 69-72. 10.1007/s10286-011-0119-5.CrossRefPubMed Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG: Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011, 21: 69-72. 10.1007/s10286-011-0119-5.CrossRefPubMed
15.
go back to reference Zhang Q, Liao Y, Tang C, Du J, Jin H: Twenty-four-hour urinary sodium excretion and postural orthostatic tachycardia syndrome. J Pediatr. 2012, 161: 281-284. 10.1016/j.jpeds.2012.01.054.CrossRefPubMed Zhang Q, Liao Y, Tang C, Du J, Jin H: Twenty-four-hour urinary sodium excretion and postural orthostatic tachycardia syndrome. J Pediatr. 2012, 161: 281-284. 10.1016/j.jpeds.2012.01.054.CrossRefPubMed
16.
go back to reference Singer W, Sletten DM, Opfer-Gehrking TL, Brands CK, Fischer PR, Low PA: Postural tachycardia in children and adolescents: what is abnormal?. J Pediatr. 2012, 160: 222-226. 10.1016/j.jpeds.2011.08.054.PubMedCentralCrossRefPubMed Singer W, Sletten DM, Opfer-Gehrking TL, Brands CK, Fischer PR, Low PA: Postural tachycardia in children and adolescents: what is abnormal?. J Pediatr. 2012, 160: 222-226. 10.1016/j.jpeds.2011.08.054.PubMedCentralCrossRefPubMed
17.
go back to reference Zhang F, Li X, Ochs T, Chen L, Liao Y, Tang C, Jin H, Du J: Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2012, 60: 315-320. 10.1016/j.jacc.2012.04.025.CrossRefPubMed Zhang F, Li X, Ochs T, Chen L, Liao Y, Tang C, Jin H, Du J: Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2012, 60: 315-320. 10.1016/j.jacc.2012.04.025.CrossRefPubMed
18.
go back to reference Qingyou Z, Junbao D, Chaoshu T: The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J Pediatr. 2006, 149: 777-780. 10.1016/j.jpeds.2006.07.031.CrossRefPubMed Qingyou Z, Junbao D, Chaoshu T: The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J Pediatr. 2006, 149: 777-780. 10.1016/j.jpeds.2006.07.031.CrossRefPubMed
19.
go back to reference Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ: Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988, 81: 213-220. 10.1172/JCI113298.PubMedCentralCrossRefPubMed Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ: Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988, 81: 213-220. 10.1172/JCI113298.PubMedCentralCrossRefPubMed
20.
go back to reference Winker R, Barth A, Dorner W, Mayr O, Pilger A, Ivancsits S, Ponocny I, Heider A, Wolf C, Rüdiger HW: Diagnostic management of orthostatic intolerance in the workplace. Int Arch Occup Environ Health. 2003, 76: 143-150.PubMed Winker R, Barth A, Dorner W, Mayr O, Pilger A, Ivancsits S, Ponocny I, Heider A, Wolf C, Rüdiger HW: Diagnostic management of orthostatic intolerance in the workplace. Int Arch Occup Environ Health. 2003, 76: 143-150.PubMed
21.
go back to reference Winker R, Barth A, Bidmon D, Ponocny I, Weber M, Mayr O, Robertson D, Diedrich A, Maier R, Pilger A, Haber P, Rüdiger HW: Endurance exercise training in orthostatic intolerance: a randomized, controlled trial. Hypertension. 2005, 45: 391-398. 10.1161/01.HYP.0000156540.25707.af.CrossRefPubMed Winker R, Barth A, Bidmon D, Ponocny I, Weber M, Mayr O, Robertson D, Diedrich A, Maier R, Pilger A, Haber P, Rüdiger HW: Endurance exercise training in orthostatic intolerance: a randomized, controlled trial. Hypertension. 2005, 45: 391-398. 10.1161/01.HYP.0000156540.25707.af.CrossRefPubMed
22.
go back to reference Chen L, Wang L, Sun J, Qin J, Tang C, Jin H, Du J: Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome. Circ J. 2011, 75: 927-931. 10.1253/circj.CJ-10-0514.CrossRefPubMed Chen L, Wang L, Sun J, Qin J, Tang C, Jin H, Du J: Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome. Circ J. 2011, 75: 927-931. 10.1253/circj.CJ-10-0514.CrossRefPubMed
23.
go back to reference Benrud-Larson LM, Sandroni P, Haythornthwaite JA, Rummans TA, Low PA: Correlates of functional disability in patients with postural tachycardia syndrome: preliminary cross-sectional findings. Health Psychol. 2003, 22: 643-648. 10.1037/0278-6133.22.6.643.CrossRefPubMed Benrud-Larson LM, Sandroni P, Haythornthwaite JA, Rummans TA, Low PA: Correlates of functional disability in patients with postural tachycardia syndrome: preliminary cross-sectional findings. Health Psychol. 2003, 22: 643-648. 10.1037/0278-6133.22.6.643.CrossRefPubMed
24.
go back to reference Bagai K, Song Y, Ling JF, Malow B, Black BK, Biaggioni I, Robertson D, Raj SR: Sleep disturbances and diminished quality of life in posturaltachycardia syndrome. J Clin Sleep Med. 2011, 7: 204-210.PubMedCentralPubMed Bagai K, Song Y, Ling JF, Malow B, Black BK, Biaggioni I, Robertson D, Raj SR: Sleep disturbances and diminished quality of life in posturaltachycardia syndrome. J Clin Sleep Med. 2011, 7: 204-210.PubMedCentralPubMed
25.
go back to reference Convertino VA, Sather TM: Effects of cholinergic and beta-adrenergic blockade on orthostatic tolerance in healthy subjects. Clin Auton Res. 2000, 10: 327-336. 10.1007/BF02322256.CrossRefPubMed Convertino VA, Sather TM: Effects of cholinergic and beta-adrenergic blockade on orthostatic tolerance in healthy subjects. Clin Auton Res. 2000, 10: 327-336. 10.1007/BF02322256.CrossRefPubMed
26.
go back to reference Stewart JM, Munoz J, Weldon A: Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation. 2002, 106: 2946-2954. 10.1161/01.CIR.0000040999.00692.F3.CrossRefPubMed Stewart JM, Munoz J, Weldon A: Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation. 2002, 106: 2946-2954. 10.1161/01.CIR.0000040999.00692.F3.CrossRefPubMed
27.
go back to reference Masuki S, Eisenach JH, Schrage WG, Johnson CP, Dietz NM, Wilkins BW, Sandroni P, Low PA, Joyner MJ: Reduced stroke volume during exercise in postural tachycardia syndrome. J Appl Physiol. 2007, 103: 1128-1135. 10.1152/japplphysiol.00175.2007.CrossRefPubMed Masuki S, Eisenach JH, Schrage WG, Johnson CP, Dietz NM, Wilkins BW, Sandroni P, Low PA, Joyner MJ: Reduced stroke volume during exercise in postural tachycardia syndrome. J Appl Physiol. 2007, 103: 1128-1135. 10.1152/japplphysiol.00175.2007.CrossRefPubMed
28.
go back to reference Thieben MJ, Sandroni P, Sletten DM, Benrud-Larson LM, Fealey RD, Vernino S, Lennon VA, Shen WK, Low PA: Postural orthostatic tachycardia syndrome: the mayo clinic experience. Mayo Clin Proc. 2007, 82: 308-313. 10.1016/S0025-6196(11)61027-6.CrossRefPubMed Thieben MJ, Sandroni P, Sletten DM, Benrud-Larson LM, Fealey RD, Vernino S, Lennon VA, Shen WK, Low PA: Postural orthostatic tachycardia syndrome: the mayo clinic experience. Mayo Clin Proc. 2007, 82: 308-313. 10.1016/S0025-6196(11)61027-6.CrossRefPubMed
29.
go back to reference Kimpinski K, Figueroa JJ, Singer W, Sletten DM, Iodice V, Sandroni P, Fischer PR, Opfer-Gehrking TL, Gehrking JA, Low PA: A prospective, 1-year follow-up study of postural tachycardia syndrome. Mayo Clin Proc. 2012, 87: 746-752. 10.1016/j.mayocp.2012.02.020.PubMedCentralCrossRefPubMed Kimpinski K, Figueroa JJ, Singer W, Sletten DM, Iodice V, Sandroni P, Fischer PR, Opfer-Gehrking TL, Gehrking JA, Low PA: A prospective, 1-year follow-up study of postural tachycardia syndrome. Mayo Clin Proc. 2012, 87: 746-752. 10.1016/j.mayocp.2012.02.020.PubMedCentralCrossRefPubMed
Metadata
Title
Orthostatic plasma norepinephrine level as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome
Authors
Qingyou Zhang
Xia Chen
Jiawei Li
Junbao Du
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-014-0249-3

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine